Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML

Blood (2015) 126 (23): 329.

https://doi.org/10.1182/blood.V126.23.329.329

Published: 2015

Journal Articles

Low Toxicity Profile of the Combination of Bendamustine Plus Rituximab (BR) in Elderly FRAIL Patients with Newly Diagnosed DLBCL

Michele Spina, MD, Stefano Luminari, MD, Flavia Salvi, Francesco Passamonti, MD, Alberto Fabbri, MD, Umberto Vitolo, MD, Maria Giuseppina Cabras, MD, Maurizio Miglino, PhD, Francesco Merli, Pier Paolo Fattori, MD, Anna Marina Liberati, MD, Alfonso Zaccaria, Patrizia Tosi, MD, Rosanna Ciancia, MD, Emanuela Anna Pesce, Sergio Storti, MD

Blood (2014) 124 (21): 4429.

https://doi.org/10.1182/blood.V124.21.4429.4429

Published: 2014

Journal Articles

4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party

Blood (2013) 122 (21): 4000.

https://doi.org/10.1182/blood.V122.21.4000.4000

Published: 2013

Journal Articles

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Stefano Sacchi, MD, Samantha Pozzi, MD, Marina Cesaretti, Luigi Marcheselli, MS, Gabriele Buda, MD, Antonio Lazzaro, MD, Luca Baldini, Francesco Di Raimondo, MD, Pellegrino Musto, MD, Alfonso Zaccaria, Giorgina Specchia, Umberto Vitolo, MD, Massimo Magagnoli, MD, Franco Silvestris, MD, Pier Paolo Fattori, MD, Patrizia Tosi, MD, Eliana Valentina Liardo, MD, Alessia Bari, MD, Angelo Michele Carella

Blood (2013) 122 (21): 4383.

https://doi.org/10.1182/blood.V122.21.4383.4383

Published: 2013

Journal Articles

A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients

Blood (2013) 122 (21): 687.

https://doi.org/10.1182/blood.V122.21.687.687

Published: 2013

Journal Articles

Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi

Blood (2013) 122 (21): 850.

https://doi.org/10.1182/blood.V122.21.850.850

Published: 2013

Journal Articles

Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib.

Blood (2012) 120 (21): 2797.

https://doi.org/10.1182/blood.V120.21.2797.2797

Published: 2012

Journal Articles

Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

Stefano Sacchi, Samantha Pozzi, Marina Cesaretti, Luigi Marcheselli, Eliana Valentina Liardo, Gabriele Buda, Antonio Lazzaro, Luca Baldini, Francesco Di Raimondo, MD, Pellegrino Musto, Alfonso Zaccaria, Giorgina Specchia, Umberto Vitolo, Massimo Magagnoli, Franco Silvestris, Pier Paolo Fattori, Patrizia Tosi, Angelo Michele Carella

Blood (2012) 120 (21): 1645.

https://doi.org/10.1182/blood.V120.21.1645.1645

Published: 2012

Journal Articles

Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

Blood (2012) 120 (21): 903.

https://doi.org/10.1182/blood.V120.21.903.903

Published: 2012

Journal Articles

Lenalidomide Is Effective in Heavily Pretreated Non Hodgkin Lymphoma (NHL): Analysis of a Retrospective Data Collection

Luigi Rigacci, MD, Umberto Vitolo, M. Christina Cox, MD, Liliana Devizzi, MD, Alberto Fabbri, MD, Alfonso Zaccaria, MD, Francesco Zaja, MD, Paolo Paesano, MD, Giuseppe Rossi, MD, Sergio Storti, Sante Tura, MD, Pier Luigi Zinzani, MD

Blood (2012) 120 (21): 3694.

https://doi.org/10.1182/blood.V120.21.3694.3694

Published: 2012

Journal Articles

Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307

Blood (2012) 120 (21): 3784.

https://doi.org/10.1182/blood.V120.21.3784.3784

Published: 2012

Journal Articles

Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).

Blood (2012) 120 (21): 2720.

https://doi.org/10.1182/blood.V120.21.2720.2720

Published: 2012

Journal Articles

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

Blood (2012) 120 (4): 761–767.

https://doi.org/10.1182/blood-2011-10-384651

Published: 2012

Journal Articles

Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial)

Blood (2011) 118 (21): 2756.

https://doi.org/10.1182/blood.V118.21.2756.2756

Published: 2011

Journal Articles

A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Blood (2011) 118 (21): 805.

https://doi.org/10.1182/blood.V118.21.805.805

Published: 2011

Journal Articles

Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies

Blood (2011) 118 (21): 112.

https://doi.org/10.1182/blood.V118.21.112.112

Published: 2011

Journal Articles

Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2 nd -Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement

Blood (2011) 118 (21): 575.

https://doi.org/10.1182/blood.V118.21.575.575

Published: 2011

Journal Articles

Long Term Efficacy of Percutaneous Vertebroplasty in Multiple Myeloma (MM) Patients: Experience of the “Gruppo Ematologico Di Romagna” (GER)

Patrizia Tosi, MD, Annalia Molinari, MD, Michele Sintini, MD, Anna Merli, MD, Michela Ceccolini, MD, Manuela Imola, MD, Paolo Savini, MD, Silvana Pasini, MD, Anna M Mianulli, MD, Barbara Castagnari, MD, Pier P Fattori, MD, Giovanni Martinelli, MD, PhD, Alfonso Zaccaria

Blood (2011) 118 (21): 5123.

https://doi.org/10.1182/blood.V118.21.5123.5123

Published: 2011

Journal Articles

Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial.

Pier Luigi Zinzani, MD, PhD, Enrico Derenzini, MD, Cinzia Pellegrini, Luigi Rigacci, Alberto Fabbri, Federica Quirini, Vittorio Stefoni, Letizia Gandolfi, Lisa Argnani, Beatrice Casadei, Alessandro Broccoli, Alessandro Pulsoni, MD, Marco Gobbi, MD, Alessio Perrotti, Alfonso Zaccaria, Maria Teresa Voso, MD, Maria Giuseppina Cabras, Amalia De Renzo, Michele Baccarani, MD

Blood (2011) 118 (21): 1604.

https://doi.org/10.1182/blood.V118.21.1604.1604

Published: 2011

Journal Articles

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Marco Montillo, Alessandra Tedeschi, Valeria Belsito Petrizzi, Francesca Ricci, Monica Crugnola, Mauro Spriano, Pierangelo Spedini, Fiorella Ilariucci, Lilj Uziel, Immacolata Attolico, Eleonora Vismara, Angelo De Blasio, Alfonso Zaccaria, Enrica Morra

Blood (2011) 118 (15): 4079–4085.

https://doi.org/10.1182/blood-2011-05-351833

Published: 2011

NARROW

Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML

Low Toxicity Profile of the Combination of Bendamustine Plus Rituximab (BR) in Elderly FRAIL Patients with Newly Diagnosed DLBCL

4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients

Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi

Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib.

Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

Lenalidomide Is Effective in Heavily Pretreated Non Hodgkin Lymphoma (NHL): Analysis of a Retrospective Data Collection

Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307

Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial)

A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies

Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2 nd -Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement

Long Term Efficacy of Percutaneous Vertebroplasty in Multiple Myeloma (MM) Patients: Experience of the “Gruppo Ematologico Di Romagna” (GER)

Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial.

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only